Drugs / GS-5718
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05165771 | Jul 2022 → Feb 2023 | rheumatoid arthritis | Gilead Sciences | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GS-5718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05165771 ↗ |
| Route | Oral | “Tablets administered orally” NCT05165771 ↗ |